Latest news with #ChrisChen
Yahoo
17-05-2025
- Business
- Yahoo
WuXi Biologics Congratulates Partner CANbridge Pharmaceuticals on the Approval of Innovative Velaglucerase-beta for Injection (Gaurunning) for Gaucher Disease by China NMPA
Enabled by WuXi Biologics' industry-leading integrated technology platform, velaglucerase-beta for injection has successfully advanced from concept to commercialization. Velaglucerase-beta for injection, as the first and the only locally developed enzyme replacement therapy (ERT) for Gaucher disease in China, marks a significant breakthrough for CANbridge Pharmaceuticals and WuXi Biologics in advancing R&D of innovative rare disease therapeutics in China. Velaglucerase-beta for injection is the first innovative biological product in China to pass segmented manufacturing inspection. WUXI, China and SHANGHAI, May 16, 2025 /PRNewswire/ -- WuXi Biologics ( a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its partner CANbridge Pharmaceuticals on the approval of its innovative velaglucerase-beta for injection (Gaurunning) by the China National Medical Products Administration (NMPA) for the treatment of adolescents aged 12 and above and adults with type I and type III Gaucher disease. This marks China's first and only locally developed enzyme replacement therapy (ERT) for Gaucher disease. Gaucher disease is a rare inherited genetic lysosomal storage disorder characterized by clinical manifestations such as hepatosplenomegaly, anemia, bone pain, and neurological symptoms, which can be life-threatening in severe cases. Recombinant human glucocerebrosidase ERT has been the standard treatment for Gaucher disease for 30 years, significantly improving major non-neurological signs and symptoms, as well as improving the quality of life for patients. It is estimated that the global prevalence of Gaucher disease is 0.7 to 1.75 per 100,000 people. Gaucher disease has been included in China's "First List of Rare Diseases". Velaglucerase-beta for injection is the first collaboration project on rare diseases between CANbridge and WuXi Biologics, advancing from concept to commercialization by leveraging WuXi Biologics' leading integrated technology platform. The project utilized innovative technology to construct high-expression cell line and achieved significant improvements in both yield and quality through WuXiUPTM, an ultra-high productivity continuous bioprocessing platform of WuXi Biologics. The overall yield increased by more than 110 times, and the specific enzyme activity increased by more than 50%, ensuring the affordability for Gaucher disease patients. Additionally, WuXi Biologics developed cell-based bioassay methods for commercial product release and stability testing, addressing the technical challenges of enzyme testing and effectively ensuring product quality control. Additionally, velaglucerase-beta for injection is the first innovative biological product in China to pass segmented manufacturing inspection. Dr. Chris Chen, CEO of WuXi Biologics, stated, "We are honored to enable CANbridge to achieve the significant milestone of approval for velaglucerase-beta for injection, which represents a critical advancement in rare disease drug innovation in China. Developing therapies for rare diseases is a long and challenging journey, requiring relentless joint efforts to bridge the gap between early-stage discovery and patients' access to medication. The successful commercialization of velaglucerase-beta for injection not only reflects CANbridge's decade-long dedication to rare diseases but also exemplifies the value of WuXi Biologics' integrated platform and CRDMO business model. Furthermore, our shared commitment to addressing the unmet clinical needs of rare disease patients has resulted in China's first locally developed ERT for Gaucher disease. We look forward to enabling more global partners to accelerate the development of high-quality rare disease therapies, and making them accessible and affordable for more patients suffering from rare diseases." Dr. James Xue, Founder, Chairman, and CEO of CANbridge Pharmaceuticals, stated, "Enzyme replacement therapy is a crucial part of CANbridge' global pipeline. The approval of velaglucerase-beta for injection in China is a milestone. By leveraging the integrated technology platform, velaglucerase-beta for injection will significantly reduce development costs, making safe and effective domestically produced ERT accessible and affordable for patients. This product is also the first collaboration project between CANbridge and WuXi Biologics in rare diseases. We extend our gratitude to our partners, including WuXi Biologics, who have empowered the development and manufacturing of velaglucerase-beta for injection. This milestone is not only CANbridge' third rare disease drug to be launched following Hunterase® and Livmarli®, but also the first in-house developed commercialized product. In the future, we will continue to focus on the localized research, manufacturing, commercialization, and accessibility of rare disease drugs, bringing innovative treatments to patients in China." Since its establishment, WuXi Biologics has been committed to enabling global innovative biotech companies to accelerate the rare disease drugs from concept to commercialization, benefiting rare disease patients worldwide. As ofthe end of 2024, there are 21 rare disease projects on the company's platform. Additionally, the company actively promotes public awareness and supports the rare disease patient community through various philanthropic initiatives. Its global "Run for Health" campaign has engaged over 2,500 participants to raise awareness for rare diseases. In China, the company's "Rare Disease Student Education Support Program" has provided scholarships to over 100 students affected by rare diseases over the past four years, fostering their academic growth. About Velaglucerase-beta for Injection (Gaurunning) Velaglucerase-beta for injection is the first domestically developed recombinant human glucocerebrosidase ERT in China, now approved for clinical use in treatment of Type I and Type III Gaucher disease patients. Most Gaucher disease patients are Type I and Type III, which are chronic non-neuronopathic and chronic neuronopathic forms, respectively. velaglucerase-beta is administered as an intravenous infusion and is intended to supplement the lack of glucocerebrosidase in the lysosomes of GD patients. The pivotal clinical trial of velaglucerase-beta achieved positive top-line data in August 2024. The velaglucerase-beta pivotal trial is a randomized, double-blind, dose-comparison study designed to evaluate the efficacy, safety, and pharmacokinetics of intravenous velaglucerase-beta administered every other week in newly treated Gaucher Disease (GD) patients, with an extension period. The results demonstrate that the study successfully met its primary efficacy endpoint, showing a statistically significant mean percentage reduction from baseline in spleen volume at nine months for both the 60 U/kg dose (P<0.0001) and the lower 30 U/kg dose (P<0.001). The primary endpoint of this trial protocol has been agreed upon by the CDE. About Gaucher Disease (GD) Gaucher disease, one of the most common lysosomal storage disorders, is a rare inherited genetic metabolic disease caused by autosomal recessive mutations in the GBA gene located on chromosome 1q22 and affects both males and females equally. Gaucher disease is a clinical spectrum that comprises Type 0 (perinatal-lethal), Type I (chronic non-neuronopathic), Type II (acute neuronopathic), and Type III (chronic neuronopathic) forms, with Types I and III surviving into adulthood. Gaucher disease is caused by a deficiency of glucocerebrosidase (acid b-glucosidase), an enzyme that helps break down a cellular membrane glycosphingolipid called glucocerebroside (glucosylceramide) inside lysosomes. As a result, glucocerebroside accumulates primarily in cells of the monocyte-macrophage lineage (Gaucher cells) within certain organs, leading to splenomegaly, hepatomegaly, anemia, thrombocytopenia, bone pain and fractures, and in the most severe forms (perinatal-lethal, Types II and III), early neurological symptoms. For 30 years, recombinant human glucocerebrosidase enzyme replacement therapy (ERT) has been the standard of care for Gaucher disease, with clinical trials and real-world data demonstrating significant improvement in the major non-neurological signs and symptoms of disease and quality of life. There were 3,000 patients with Gaucher disease in China in 2020, according to Frost & Sullivan. Gaucher disease has been included in China's "First List of Rare Diseases." About WuXi Biologics WuXi Biologics (stock code: is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide. With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects). WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain. For more information about WuXi Biologics, please visit: About Canbridge CANbridge Pharmaceuticals Inc. (HKEX:1228) is a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies for rare disease. CANbridge has a differentiated drug portfolio, with 3 approved drugs and a pipeline of 8 assets, targeting prevalent rare disease indications that have unmet needs and significant market potential. These include Hunter syndrome and other lysosomal storage disorders, complement-mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases. The CANbridge Next-Generation Innovation and Process Development Facility is developing novel, potentially curative, gene therapies for rare genetic diseases, including Pompe disease, Fabry disease, spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD) and other neuromuscular conditions, and collaborates with world-leading researchers and biotech companies. CANbridge global partners include: Apogenix, GC Pharma, Mirum, Wuxi Biologics, Privus, UMass Chan Medical School, the University of Washington School of Medicine and Scriptr Global. For more on CANbridge Pharmaceuticals Inc., please go to: Contacts Businessinfo@ MediaPR@ View original content: SOURCE WuXi Biologics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
15-05-2025
- Business
- Business Insider
How to invest a lump sum of money at any age
Investing a windfall requires considering age, risk tolerance, and financial goals. Younger investors can afford more risk, while older investors should focus on stability. Consult a financial planner to tailor investment strategies to individual circumstances. It's the age-old question when you suddenly come into a bit of money: What should you do with it? Temptations lurk. That bucket-list trip to St. Bart's. The Mercedes C-Class convertible you've always wanted. A seahorse-shaped potato chip currently going for $105,000 on eBay. Oh, that's just me? While the pull of instant gratification is strong, perhaps you've come to the more responsible decision to invest the money. Even then, it's difficult to know where to put your new lump sum. The answer will differ for everyone, depending on when they'll need the money and what their risk tolerance is. But we thought a general guide may be useful for people of all ages who've just received a chunk of money like a bonus, an inheritance, or a tax return. With the help of Chris Chen, a certified financial planner and the founder of Insight Financial Strategists, we've come up with a plan that investors can think about taking with a new windfall, no matter how old they are. While it's impossible to personalize a plan for each individual, the assumption in this case is that the cash will be put aside for retirement. Disclaimer: this is not specialized financial advice, and each investor should consider their own circumstances and consult a financial professional before making decisions. Check out your suggested path below. 20-29 Open a brokerage account. Not a 401(k) or a Roth IRA — those should be set up with an employer and contributed to regularly. Setting up a separate account with a brokerage firm like Vanguard or Ally will prevent you from having to pay penalties if you need the money before retirement age. Once that's done, allocate 80% of the money to stocks and 20% to bonds. The classic portfolio construction is 60% stocks and 40% bonds, but your longer investing timeline means you can withstand the volatility of the stock market. A 20% allocation to bonds will still provide some downside protection. Within stocks, put most of your money into an index fund like the SPDR Portfolio S&P 500 ETF (SPLG). To diversify, allocate around 5-10% to international stocks through a fund like the Schwab International Equity ETF (SCHF). 30-39 Perhaps you already have a stock portfolio. It's not a bad idea to simply throw a new lump sum into existing positions, or into a broad index fund that will grow over a decadeslong period. It could also be a good opportunity to assess how your portfolio is structured, and think about how you can perhaps rebalance with some international exposure it so you're properly diversified. You may also want to diversify into another asset class: real estate. If it's enough money for a down payment, you could lose the lump sum to buy a home. Mortgage rates admittedly aren't great at the moment, but you can always refinance if rates drop in the future. People increasingly have their first kid in their 30s. If that's the case for you, maybe open a 529 plan for college savings. If you're not a parent yet but plan on being one sometime down the line, you can open up a 529 plan for yourself, as the funds can be used for anyone in your family. 40-49 You're starting to get closer to retirement age, but assuming a retirement age of 65, you still probably have enough time to keep your equity exposure aggressive. Put 80% of the money into an S&P 500 index fund and 20% into bonds through a fund like the iShares Core US Aggregate Bond ETF (AGG). If you're lucky enough to feel like you're pretty well covered on your own retirement needs, you might consider opening up a Roth IRA for your kids, if you have them. 50-59 Retirement is on the horizon, so you should start taking a more cautious and active approach to money management. At this point, it's a good idea to hire a Certified Financial Planner to develop a plan that's unique to your needs. A generally good idea heading into retirement is to start building up a three-year "safe bucket," which is enough living expenses to cover three years. You'll have this money in low-risk, shorter-term bonds. Any leftover money can go into stock-market index funds. Stocks are risky and volatile investments that can be subject to significant downside in a short period of time. That's why it's good to have an investing timeline of at least a few years, or even better, more than a decade. 60+ It's the same advice for those in their 50s: start building up enough funds to cover three years of living expenses. These funds will be invested in safe-haven short-term bonds. Extra money can go into a stock-market index fund, though it may be a good idea to allocate part of your stock portfolio to more defensive areas of the market since your investing timeline starts to shorten. Once you retire, you'll start to sell your bond positions year by year to fund your spending. As you sell the bonds, you'll need to sell an equivalent amount in stock positions to keep your "safe bucket" three years deep. The calculus on how much money you'll need to pull out of your portfolio does start to change a bit once you're able to start claiming Social Security as early as 62.
Associated Press
22-04-2025
- Business
- Associated Press
WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year
SHANGHAI, April 22, 2025 /PRNewswire/ -- WuXi Biologics ('WuXi Bio') ( a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been recognized by CDP, the world's foremost environmental non-profit reporting organization, for its leadership in disclosure transparency and performance excellence in the area of climate change. This marks the second consecutive year the company has achieved this honor. CDP is recognized as the global standard for corporate environmental reporting, and its annually published ratings are widely used to drive investment and procurement decisions toward a net-zero, sustainable and resilient economy. Companies are evaluated on their awareness of environmental issues, management methods and advancements in environmental stewardship. In 2024, nearly 25,000 companies — representing two-thirds of the global market value — reported their environmental data through CDP. WuXi Biologics stood out among these companies with an 'A-" score for leadership on climate change. Committed to the Science Based Target initiative (SBTi), WuXi Biologics has adopted an integrated strategy to tackle climate change issues, with measurable targets and a refined roadmap. The Company aims to achieve net-zero emissions from overall operations by 2050, and in 2024, it realized a 30% GHG (Scope 1 and Scope 2) emission intensity reduction from the base year 2020. The company also actively pursues opportunities to decrease energy consumption, advocating energy-saving initiatives from process optimization, equipment upgrade, and infrastructure replacement and renovation. The company actively deploys rooftop photovoltaic power projects, and has achieved a 100% renewable electricity supply at its Ireland site. Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, 'We are very pleased to be recognized once again by CDP for climate change leadership, an acknowledgement that further inspires our steadfast dedication to enhancing our sustainability performance. It is fitting that we are making this announcement on Earth Day as we, along with organizations and communities around the world, put special focus on the importance of long-term ecological sustainability. As a global leader in Green CRDMO, we consistently deliver ESG excellence, enable partners worldwide with end-to-end solutions to fulfil their ESG commitments, and work together with all of our stakeholders to promote responsible practices throughout the entire value chain.' As a participant of the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively advocates sustainability, and has earned widespread recognition for its efforts. It was granted an MSCI AAA Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI) for two consecutive years; included in the UNGC 20 Case Examples of Sustainable Development for 20 Years Collection for its world-leading green biologics solutions; recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; merited an 'A' CDP Water Security score; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating. About CDP CDP is a global non-profit that runs the world's only independent environmental disclosure system. As the founder of environmental reporting, the organization believes in transparency and the power of data to drive change. Partnering with leaders in enterprise, capital, policy and science, CDP surfaces the information needed to enable Earth-positive decisions. It helped more than 24,800 companies and 1,100 cities, states and regions disclose their environmental impacts in 2024. Financial institutions with more than a quarter of the world's institutional assets use CDP data to help inform investment and lending decisions. Aligned with the ISSB's climate standard, IFRS S2, as its foundational baseline, CDP integrates best-practice reporting standards and frameworks in one place. The team is truly global, united by a shared desire to build a world where people, planet and profit are truly balanced. About WuXi Biologics WuXi Biologics (stock code: is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide. With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects). WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain. For more information about WuXi Biologics, please visit: View original content: SOURCE WuXi Biologics
Yahoo
04-04-2025
- Automotive
- Yahoo
Nio Begins European Layoffs to Cut Global Costs by 25%
Nio (NIO, Financials) is starting to lay off employees in its European operations as part of a cost-cutting plan intended to lower global operational expenses by 25%, according to two individuals with direct knowledge of the matter. Warning! GuruFocus has detected 5 Warning Signs with NIO. The job reductions are concentrated in the electric vehicle maker's design and research and development teams, the people said. Employees affected by the layoffs were reportedly informed during internal meetings held on Friday and through private messaging platforms. The company has not issued a formal announcement or internal memo regarding the decision. The global business unit, which includes regions overseen by executive Chris Chen, remains unaffected at this time, one of the sources said. However, additional workforce reductions may follow in the coming weeks as the company continues to evaluate its cost structure. The layoffs reflect growing pressure on electric vehicle makers to reduce costs amid slowing demand and heightened competition in key markets such as Europe. Nio has previously undertaken similar cost-reduction initiatives in China, where the company has faced margin compression and a price war triggered by local rivals. Nio has not responded to public requests for comment, and no statement has been published on its investor relations page. Founded in 2014, Nio has positioned itself as a premium electric vehicle brand in China and expanded operations into Europe in recent years. The company's stock has declined more than 8% over the past week, underperforming peers such as XPeng (XPEV, Financials) and Li Auto (LI, Financials). According to its most recent quarterly report, Nio delivered just over 50,000 vehicles, falling short of internal projections. Analysts say further belt-tightening may be required if delivery volumes do not recover in the coming quarters. The company trades on the New York Stock Exchange under the symbol NIO. This article first appeared on GuruFocus. Sign in to access your portfolio
Associated Press
21-03-2025
- Business
- Associated Press
WuXi Biologics Named to CDP Water Security "A List" for Second Consecutive Year
Launching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development Goal 6 (SDG6) Contributing to the 2025 World Water Day campaign to ensure the availability of water and sanitation for all SHANGHAI, March 20, 2025 /PRNewswire/ -- WuXi Biologics ('WuXi Bio') ( a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been recognized by the environmental non-profit CDP for leadership in corporate transparency and performance on water security, securing a place on the organization's annual 'A List' for the second year. According to CDP's scoring methodology, companies are evaluated on their awareness of environmental issues, management methods and advancements in environmental stewardship. Assessments are conducted across four levels that represent the steps a company moves through on its action journey: Disclosure (D-/D score), Awareness (C-/C score), Management (B-/B score), Leadership (A/A- score). Based on data reported through the CDP 2024 Assessment Questionnaire, WuXi Biologics achieved a score of 'A' for Water Security, standing out among over 25,000 companies evaluated. As a contributor to the United Nations Sustainable Development Goal 6 (SDG6), WuXi Biologics has adopted a systematic approach to enhance environment-friendly water management and help ensure the availability of water and sanitation for all. Various proactive measures regarding water are employed: measuring, avoiding, reducing and recycling. The company has set a target to reduce water consumption intensity by 30% by 2025 from the base year 2019. Reaffirming its dedication to good water stewardship and commitment to sustainable water management, the company launched a Water Excellence Stewardship (WES) program covering water governance, water balance, water quality, safe water/environmental and personal hygiene (WASH), and other material topics. Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, 'We are very pleased to be named once again on the CDP Water Security 'A' list, an acknowledgement that further inspires our steadfast dedication to enhancing our sustainability performance. As a global leader in Green CRDMO, we consistently deliver ESG excellence, enable partners worldwide to fulfill ESG commitments, and jointly work with all stakeholders to promote responsible practices throughout the entire value chain.' As a participant of the United Nations Global Compact (UNGC) and Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively advocates sustainability, and has earned widespread recognition for its efforts. It was granted an MSCI AAA Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI) for two consecutive years; included in the UNGC 20 Case Examples of Sustainable Development for 20 Years Collection for its world-leading green biologics solutions; recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; merited an 'A-" CDP Climate Change score; selected as a Constituent of the FTSE4Good Index Series; and listed in the Hang Seng ESG 50 Index. About CDP CDP is a global non-profit that runs the world's only independent environmental disclosure system. As the founder of environmental reporting, the organization believes in transparency and the power of data to drive change. Partnering with leaders in enterprise, capital, policy and science, CDP surfaces the information needed to enable Earth-positive decisions. It helped more than 24,800 companies and 1,100 cities, states and regions disclose their environmental impacts in 2024. Financial institutions with more than a quarter of the world's institutional assets use CDP data to help inform investment and lending decisions. Aligned with the ISSB's climate standard, IFRS S2, as its foundational baseline, CDP integrates best-practice reporting standards and frameworks in one place. The team is truly global, united by a shared desire to build a world where people, planet and profit are truly balanced. About WuXi Biologics WuXi Biologics (stock code: is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide. With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects). WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain. For more information about WuXi Biologics, please visit: . Contacts ESG [email protected] Media [email protected] View original content: SOURCE WuXi Biologics
